Investor Relations · The Share
The Novogenia AG share
Everything for shareholders and the capital market: the live share price on XETRA and the Munich Stock Exchange, analyst coverage, dividend history, financial reports and the people leading the company.
The Novogenia Stock
Live price development on XETRA / Munich, with the key facts of the Novogenia AG share.
Analyst price targets
What independent analysts say about the Novogenia AG share — each broker’s rating, 12-month price target and full research note.
Third-party analyst opinions (ODDO BHF and GBC Research), reproduced for information only — not investment advice or a recommendation by Novogenia AG.
Dividends
Novogenia AG follows a dividend strategy: as long as the development of the company is not impeded, it aims to pay a dividend to its shareholders every year.
Total payout = dividend per share × 12,000,000 shares outstanding. The 2025 dividend is subject to approval by the Annual General Meeting.
Financial Reports
Annual, consolidated, half-year and issuer reports for the Novogenia AG share, newest first. Reports published before the 26 June 2026 rename appear under the company’s former name, Darwin AG.
2025
ReportPDFConsolidated Financial Statements 2025Annual Report · PDFDownload ReportPDFFinancial Statement Darwin AG 2025Annual Report · PDFDownload ReportPDFQuarterly Release Darwin AG Q3 2025Quarterly Report · PDFDownload ReportPDFIssuer Report Darwin AG 2025Annual Report · PDFDownload2024
ReportPDFConsolidated Financial Statement 2024Annual Report · PDFDownload ReportPDFFinancial Statement Darwin AG 2024Annual Report · PDFDownload ReportPDFIssuer Report as of 30.06.2024Half-Year Report · PDFDownload2023
ReportPDFConsolidated Financial Statement 2023Annual Report · PDFDownload ReportPDFFinancial Statement Darwin AG 2023Annual Report · PDFDownload2022
ReportPDFConsolidated Financial Statement 2022Annual Report · PDFDownload2021
ReportPDFFinancial Statement Darwin AG 2021Annual Report · PDFDownload ReportPDFConsolidated Financial Statement 2021Annual Report · PDFDownloadLeadership
The people leading Novogenia AG.
Dr. Daniel Wallerstorfer PhD, BSc
Molecular biologist with a PhD in Biotechnology and founder of Novogenia. Daniel built the company into a leading laboratory for genetic testing and personalized health, driving the Group’s research, technology and product innovation. During the COVID-19 pandemic the group became a leading SARS-CoV-2 testing laboratory, and the holding company was listed on the Munich Stock Exchange. He is also a science author who educates the public about the power of our genes.
Management Board
Felix Bausch
Member of the Management Board, leading Investor Relations and Mergers & Acquisitions for the Group from Munich — managing the capital-market relationships and the acquisition pipeline that drive Novogenia’s growth strategy.
Matthias Probst Mag. (FH)
Co-founder of Novogenia GmbH and Chief Financial Officer of the Group. Matthias oversees finance across the holding and its operating companies, providing the financial foundation for the Group’s expansion.
Supervisory Board
Christian Dreyer Dipl.-Ing., MBA
Chairman of the Supervisory Board, bringing capital-market and governance experience to the oversight of Novogenia AG and the long-term interests of its shareholders.
Florian Renner
Vice Chairman of the Supervisory Board, supporting the governance and strategic oversight of Novogenia AG alongside the Chairman and contributing capital-market expertise.
Caroline Probst
Member of the Supervisory Board, contributing expertise in finance and controlling to the board’s oversight of the Group’s financial management and reporting.
Annual General Meeting
The most recent Annual General Meeting (26 June 2026) approved a €0.56 per-share dividend, discharged the Management and Supervisory Board, and approved renaming the company from Darwin AG to Novogenia AG. Full details in the AGM press release.
Investor & press contact
Questions from shareholders, analysts or media? Our Investor Relations team is happy to help.